Anova Enterprises and Nouveau Biosciences Partner to Advance Clinical Development of Kromastat for Hard-to-Treat Cancers
Anova Enterprises, Inc., a technology-enabled contract research organization (CRO) dedicated to accelerating the development of innovative therapies, has announced a strategic partnership with Nouveau Biosciences, Inc. to support the clinical development of Kromastat, the biotechnology company’s lead investigational anticancer therapy. The collaboration marks an important step in advancing a novel nanomedicine platform designed to improve targeted cancer treatment while addressing significant unmet needs in oncology.
Through the partnership, Anova will manage and support cancer-focused clinical trials for Kromastat by utilizing its proprietary AnovaOS® clinical development platform, helping Nouveau Biosciences efficiently move its lead candidate from early-stage clinical evaluation toward later-stage development. The companies aim to accelerate the delivery of promising therapies for patients with aggressive cancers that currently have limited treatment options.
The agreement reflects a shared commitment to combining innovative science with advanced clinical trial execution in order to improve the speed, quality, and efficiency of oncology drug development.
Partnership Designed to Accelerate Clinical Development
The collaboration brings together two organizations with complementary strengths.
Nouveau Biosciences contributes its proprietary nanomedicine technology platform and oncology research expertise, while Anova provides technology-driven clinical development capabilities, operational support, and trial management infrastructure.
Together, the companies intend to streamline the clinical development pathway for Kromastat, reducing development timelines while maintaining rigorous scientific and regulatory standards.
By integrating Anova’s technology-enabled clinical trial platform into Nouveau Biosciences’ development strategy, the partnership seeks to improve trial execution, optimize patient enrollment, and generate high-quality clinical data needed for future regulatory submissions.
Addressing Unmet Needs in Oncology
Cancer remains one of the world’s leading causes of death, with many aggressive malignancies continuing to have poor survival rates despite advances in treatment.
Although immunotherapies, targeted therapies, and precision medicines have transformed care for certain cancers, many patients with difficult-to-treat tumors still experience limited treatment options or eventually develop resistance to existing therapies.
Pancreatic cancer, aggressive leukemias, and certain T-cell malignancies remain particularly challenging because they often respond poorly to conventional treatment and are associated with high relapse rates.
The companies believe that Kromastat’s novel design may offer an opportunity to improve therapeutic outcomes by delivering highly potent anticancer agents more precisely to tumor tissue while minimizing toxicity.
Nouveau Biosciences’ Nanomedicine Platform
Nouveau Biosciences has developed a proprietary drug discovery platform that combines advanced medicinal chemistry with polymer-based nanotechnology.
The company’s technology is designed to create targeted nanomedicines capable of improving the delivery of anticancer drugs.
Traditional chemotherapy drugs often circulate throughout the body, exposing healthy tissues to toxic effects while only a portion of the administered dose reaches tumor cells.
Nanomedicine seeks to overcome these limitations by packaging therapeutic compounds into nanoscale delivery systems engineered to improve tumor targeting.
According to Nouveau Biosciences, its polymer-based nanochemistry platform is intended to:
- Improve drug targeting
- Enhance therapeutic efficacy
- Increase treatment tolerability
- Reduce systemic toxicity
- Support the development of first-in-class oncology therapies
The platform enables researchers to redesign potent therapeutic compounds in ways that optimize their delivery while potentially expanding their clinical utility.
Introducing Kromastat
Kromastat, previously known as NBS-M001, is the lead therapeutic candidate emerging from Nouveau Biosciences’ technology platform.
The investigational treatment consists of a polymeric nanoparticle (PNP) formulation containing a highly potent epigenetic therapeutic agent.
Epigenetic drugs work by modifying gene expression rather than altering the underlying DNA sequence.
Many cancers rely on abnormal epigenetic regulation to promote uncontrolled cell growth, resist treatment, and evade the immune system.
By targeting these regulatory mechanisms, epigenetic therapies may interfere with cancer progression while restoring more normal cellular behavior.
According to the company, incorporating the drug into a polymeric nanoparticle allows more selective delivery while potentially improving both safety and therapeutic activity.
Promising Preclinical Findings
Preclinical research has generated encouraging results across several difficult-to-treat cancers.
According to Nouveau Biosciences, Kromastat has demonstrated particularly strong activity in laboratory and animal models involving:
- Pancreatic cancer
- Aggressive leukemias
- T-cell malignancies
Among these indications, pancreatic cancer represents one of the greatest unmet medical needs.
Despite advances in oncology, pancreatic cancer continues to have one of the lowest survival rates among major cancers.
Patients are frequently diagnosed after the disease has already spread, limiting treatment options.
Similarly, aggressive leukemias and certain T-cell cancers often require intensive therapy and remain associated with high relapse rates.
The company believes Kromastat’s mechanism of action may offer a differentiated approach for these challenging diseases.
Transitioning to Clinical Evaluation
Building upon encouraging preclinical findings, Nouveau Biosciences is preparing to begin its First-in-Human clinical trial.
The initial study will evaluate the safety, tolerability, pharmacokinetics, and early signs of biological activity of Kromastat in cancer patients.
The trial will be conducted at several leading academic medical centers in Australia, a country recognized for its efficient clinical research infrastructure and strong oncology trial network.
Conducting early-stage clinical studies in Australia often allows biotechnology companies to generate important human safety data while benefiting from streamlined regulatory pathways.
The results from the First-in-Human study will inform subsequent clinical development plans.
Pathway Toward Phase 2 Development
Following completion of the initial clinical evaluation, Nouveau Biosciences intends to rapidly advance Kromastat into Phase 2 clinical studies in the United States.
The company plans to pursue a 505(b)(2) regulatory strategy, which may allow developers to rely partly on existing scientific knowledge while generating new evidence supporting their specific product.
This regulatory pathway has the potential to reduce development time and cost when appropriate scientific and regulatory criteria are met.
By combining early Australian clinical experience with subsequent U.S. development, Nouveau Biosciences aims to accelerate the path toward later-stage studies.
Anova’s Role in Clinical Development
Anova will play a central role in supporting the execution of Kromastat’s clinical program.
The company specializes in technology-enabled clinical research and has developed the proprietary AnovaOS® platform, which integrates multiple components of clinical trial management into a unified system.
The platform is designed to improve efficiency across numerous aspects of clinical research, including:
- Study planning
- Site management
- Patient enrollment
- Data collection
- Trial oversight
- Operational decision-making
By providing real-time visibility into trial operations, Anova aims to reduce delays while supporting high-quality clinical execution.
Leveraging Digital Clinical Trial Infrastructure
Technology has become increasingly important in modern clinical development.
Digital platforms help research organizations manage growing trial complexity by improving communication, automating workflows, and enabling more efficient data management.
For oncology studies—which often involve multiple treatment centers, complex eligibility criteria, and intensive patient monitoring—technology-enabled operations can significantly improve execution.
Through AnovaOS®, investigators, sponsors, and clinical teams gain access to integrated tools that support faster study activation and more coordinated trial management.
The companies expect these capabilities to help accelerate Kromastat’s development program.
Leadership Highlights Collaboration
Chris Beardmore, Chief Executive Officer of Anova, described the collaboration as an opportunity to combine innovative science with advanced clinical execution.
According to Beardmore, Nouveau Biosciences has developed a highly differentiated nanomedicine platform with the potential to reshape future cancer treatment.
He noted that integrating this technology with Anova’s clinical delivery platform will help shorten development timelines while improving operational certainty.
Beardmore emphasized that the ultimate objective is to deliver innovative therapies to patients more quickly and efficiently without compromising scientific quality.
Nouveau Biosciences Emphasizes Strategic Execution
Owen A. O’Connor, M.D., Ph.D., Chief Executive Officer and Chairman of Nouveau Biosciences, highlighted the importance of strategic partnerships in accelerating biotechnology innovation.
He explained that successful drug development depends not only on scientific discovery but also on disciplined clinical execution.
By partnering with Anova, Nouveau Biosciences expects to integrate its nanomedicine platform into an experienced clinical development infrastructure capable of supporting efficient study execution.
Dr. O’Connor stated that the collaboration is expected to reduce development risk while enabling the company to advance promising therapies with greater urgency.
Growing Interest in Targeted Nanomedicine
The partnership reflects broader trends across oncology research.
Nanomedicine has attracted increasing attention because it offers the potential to improve drug delivery while reducing treatment-related toxicity.
Researchers continue exploring nanoscale therapeutic systems capable of:
- Delivering drugs directly to tumors
- Enhancing drug stability
- Improving pharmacokinetics
- Reducing exposure to healthy tissues
- Supporting combination therapies
Although several nanomedicine products have already reached clinical practice, continued innovation is expanding opportunities to develop increasingly sophisticated targeted therapies.
Nouveau Biosciences’ polymer-based nanoparticle technology represents one example of this evolving field.
Shared Vision for Cancer Innovation
Both organizations emphasized that the partnership extends beyond a single clinical program.
The collaboration represents a broader commitment to accelerating the translation of innovative scientific discoveries into therapies that can benefit patients facing serious cancers.
Combining advanced drug discovery technologies with modern clinical trial infrastructure creates opportunities to improve development efficiency while maintaining strong scientific and regulatory standards.
As oncology becomes increasingly personalized and technology-driven, collaborations between biotechnology innovators and specialized CROs are expected to play an increasingly important role in bringing new therapies to market.
The partnership between Anova Enterprises and Nouveau Biosciences represents an important milestone in the clinical advancement of Kromastat, a novel polymeric nanoparticle-based epigenetic therapy designed for difficult-to-treat cancers. By combining Nouveau Biosciences’ innovative nanomedicine platform with Anova’s technology-enabled clinical development capabilities, the companies aim to accelerate the transition from promising preclinical research to meaningful clinical outcomes.
With a First-in-Human study planned at leading Australian academic medical centers, followed by anticipated Phase 2 development in the United States, Kromastat is positioned to enter the next stage of evaluation as investigators seek new treatment options for pancreatic cancer, aggressive leukemias, T-cell malignancies, and other cancers with significant unmet medical needs. If successful, the collaboration could contribute to the development of a new generation of targeted cancer therapies that improve both efficacy and patient quality of life while advancing the broader field of precision oncology.
About Nouveau Biosciences
Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer.
Its polymer based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company’s lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.
For more information, please visit: www.nouveaubiosciences.com
About Anova
Anova is technology enabled concierge research organization committed to accelerating clinical development of promising new therapies for biopharmaceutical companies and other sponsors utilizing the company’s proprietary technology platform (AnovaOS™).